<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9930">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05687279</url>
  </required_header>
  <id_info>
    <org_study_id>VAD00014</org_study_id>
    <secondary_id>U1111-1278-3910</secondary_id>
    <nct_id>NCT05687279</nct_id>
  </id_info>
  <brief_title>Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to &lt; 24 Months of Age in Puerto Rico (USA)</brief_title>
  <official_title>Phase II, Randomized, Observer-blind, Placebo-controlled, Multi-center Study of a Live Attenuated Respiratory Syncytial Virus Vaccine to Assess the Vaccine Virus' Transmissibility in Household or Daycare Center Settings, Shedding, and Genetic Stability, and to Describe the Immunogenicity and Safety of the Vaccine in Infants and Toddlers 6 to &lt; 24 Months of Age in Puerto Rico (USA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to assess the shedding, transmission, and genetic&#xD;
      stability of the live-attenuated RSVt vaccine after each intranasal vaccination (56 days&#xD;
      apart) in infants and toddlers 6 to &lt; 24 months of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of each participant's participation is up to 8 months, including the 6 months&#xD;
      safety follow-up phone call after the second study intervention administration for the&#xD;
      pediatric participants The treatment administration for the pediatric participants will be on&#xD;
      D01 and D57 (1 intranasal administration each).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2023</start_date>
  <completion_date type="Anticipated">November 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 21, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Observer-blind:&#xD;
Blinding for vaccine group assignment: participants, parents or legally acceptable representative (LAR), outcome assessors, investigators, laboratory personnel, Sponsor study staff&#xD;
No blinding for study staff who prepare and administer the study interventions</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of vaccine virus</measure>
    <time_frame>Day 1 through Day 22</time_frame>
    <description>Proportion of vaccinees infected with vaccine virus in the placebo group, defined as vaccine virus shedding, detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Geometric Mean Titers (GMTs) of vaccine virus shedding</measure>
    <time_frame>Day 1 through Day 71</time_frame>
    <description>Titer of vaccine virus shedding in nasal swabs, quantified by qRT-PCR Assay in all pediatric participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of differences detected in genetic sequence of NS2 segment</measure>
    <time_frame>Approximately Day 1 through Day 85</time_frame>
    <description>Number of differences detected in genetic sequence of NS2 segment of the vaccine virus compared to the reference strain vaccine virus isolates in the vaccine virus positive swabs from pediatric participants receiving placebo and ad hoc close contact participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of RSV A serum neutralizing antibody (nAb) titers</measure>
    <time_frame>Day 1, Day 57 and Day 85</time_frame>
    <description>RSV A serum Nab titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs of RSV serum anti-F Immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) antibody titers up to 28 days after the second administration (D01, D57, and D85)</measure>
    <time_frame>Day 1, Day 57 and Day 85</time_frame>
    <description>RSV serum anti-F IgG ELISA antibody titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of immediate unsolicited systemic Adverse Events (AEs)</measure>
    <time_frame>Within 30 minutes after each vaccination administration</time_frame>
    <description>Number of participants experiencing immediate unsolicited systemic AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of solicited injection site or systemic reactions</measure>
    <time_frame>Within 21 days after each vaccination administration</time_frame>
    <description>Number of participants reporting:&#xD;
injection site reactions: pain, erythema and swelling&#xD;
systemic reactions: fever, headache, malaise, myalgia, arthralgia and chills</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of unsolicited AEs</measure>
    <time_frame>Within 28 days after each vaccination administration</time_frame>
    <description>Number of participants experiencing unsolicited AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of adverse events of special interest (AESIs)</measure>
    <time_frame>Within 28 days after each vaccination administration</time_frame>
    <description>Number of participants experiencing AESIs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of medically attended adverse events (MAAEs)</measure>
    <time_frame>Within 28 days after each vaccination administration</time_frame>
    <description>Number of participants experiencing MAAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of serious adverse events (SAEs)</measure>
    <time_frame>From Day 1 until the end of the study (approximately 8 months)</time_frame>
    <description>Number of participants experiencing SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of vaccine virus at Day 64 through Day 71</measure>
    <time_frame>Day 64 through Day 71</time_frame>
    <description>Proportion of vaccinees infected with vaccine virus in the placebo group, defined as vaccine virus shedding, detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Respiratory Syncytial Virus Infection</condition>
  <arm_group>
    <arm_group_label>RSVt Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 intranasal administrations (56 days apart) of the RSVt vaccine at D01 and D57</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 intranasal administrations (56 days apart) of the placebo at D01 and D57</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSVt Vaccine</intervention_name>
    <description>Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal</description>
    <arm_group_label>RSVt Vaccine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 6 months to &lt; 24 months on the day of inclusion (from the day of the 6 months&#xD;
             after birth to the day before the 2nd birthday)&#xD;
&#xD;
          -  Participants who are healthy as determined by medical evaluation including medical&#xD;
             history.&#xD;
&#xD;
          -  Born at full term of pregnancy (â‰¥ 37 weeks) or born after a gestation period of 27&#xD;
             through 36 weeks and medically stable as assessed by the investigator, based on the&#xD;
             following definition: &quot;Medically stable&quot; refers to the condition of premature infants&#xD;
             who do not require significant medical support or ongoing management for debilitating&#xD;
             disease and who have demonstrated a clinical course of sustained recovery by the time&#xD;
             they receive the first dose of study intervention&#xD;
&#xD;
          -  Attends a daycare facility at least 3 days per week and 4 hours per day at which the&#xD;
             participant would be in a contact group/playroom of at least one other child 6 to &lt; 24&#xD;
             months of age who will participate in this study or is a member of a household, which&#xD;
             includes at least one other child 6 to &lt; 24 months of age who will participate in this&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected congenital or acquired immunodeficiency; or receipt of&#xD;
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,&#xD;
             within the preceding 6 months; or long-term systemic corticosteroid therapy&#xD;
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)&#xD;
&#xD;
          -  Known systemic hypersensitivity to any of the study intervention components, or&#xD;
             history of a life-threatening reaction to the study intervention used in the study or&#xD;
             to a product containing any of the same substances&#xD;
&#xD;
          -  Chronic illness that, in the opinion of the investigator, is at a stage where it might&#xD;
             interfere with study conduct or completion&#xD;
&#xD;
          -  Any acute febrile illness in the past 48 hours that according to investigator judgment&#xD;
             is significant enough to interfere with successful inoculation on the day of&#xD;
             vaccination. A prospective participant should not be included in the study until the&#xD;
             condition has resolved or the febrile event has subsided.&#xD;
&#xD;
          -  Probable or confirmed ongoing case of COVID-19 at the time of enrollment&#xD;
&#xD;
          -  Member of a household that contains an immunocompromised individual, including, but&#xD;
             not limited to:&#xD;
&#xD;
               -  a person who is HIV infected&#xD;
&#xD;
               -  a person who has received chemotherapy within the 12 months prior to study&#xD;
                  enrollment&#xD;
&#xD;
               -  a person who has received (within the past 6 months) or is receiving (at the time&#xD;
                  of enrollment) immunosuppressant agents&#xD;
&#xD;
               -  a person living with a solid organ or bone marrow transplant&#xD;
&#xD;
          -  Member of a household that includes, or will include, an infant who is less than 6&#xD;
             months of age at the time of enrollment&#xD;
&#xD;
          -  Attends a daycare facility and shares a daycare room with infants less than 6 months&#xD;
             of age, and parent/legally acceptable representative is unable or unwilling to suspend&#xD;
             attendance at the daycare facility for 28 days following study intervention&#xD;
             administration&#xD;
&#xD;
          -  Any need of supplemental oxygen therapy in a home or hospital setting at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Participant's mother previous receipt or planned administration of an investigational&#xD;
             RSV vaccine or any monoclonal antibody (such as Infliximab) during pregnancy and/or&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Receipt or planned receipt of any of the following vaccines prior to or after the&#xD;
             first study intervention administration:&#xD;
&#xD;
               -  any influenza vaccine within 7 days prior to and after, or any COVID-19 or&#xD;
                  inactivated vaccine or live-attenuated rotavirus vaccine within 14 days prior to&#xD;
                  and after, or&#xD;
&#xD;
               -  any live vaccine, other than rotavirus vaccine, within 28 days prior to and after&#xD;
&#xD;
          -  Previous receipt of an investigational RSV vaccine or receiving any anti-RSV product&#xD;
             (such as ribavirin or RSV Immunoglobulin (IG) or RSV monoclonal antibody) at the time&#xD;
             of enrollment.&#xD;
&#xD;
          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months&#xD;
&#xD;
          -  Receipt of intranasal and intra-ocular medications within 3 days prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Receipt at the time of enrollment or previous receipt of salicylate (aspirin) or&#xD;
             salicylate-containing products&#xD;
&#xD;
          -  Participation at the time of study enrollment (or in the 6 weeks preceding the first&#xD;
             study intervention administration) or planned participation during the present study&#xD;
             period in another clinical study investigating a vaccine, drug, medical device, or&#xD;
             medical procedure&#xD;
&#xD;
          -  Deprived of freedom in an emergency setting, or hospitalized involuntarily&#xD;
&#xD;
          -  Identified as a natural or adopted child of the Investigator or employee with direct&#xD;
             involvement in the proposed study&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a potential&#xD;
        participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :6300002</name>
      <address>
        <city>Carolina</city>
        <zip>984</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6300003</name>
      <address>
        <city>Guayama</city>
        <zip>00784</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6300001</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>January 6, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>February 25, 2023</last_update_submitted>
  <last_update_submitted_qc>February 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

